UNSPSC 51151672: Tiemonium iodide

This classification denotes an antimuscarinic agent, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier FZ2LZ7U304. European Medicines Agency schedules Tiemonium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11031MIG. Tiemonium iodide generally arises in the molecular formula C18H24INO2S. The term TIEMONIUM IODIDE is an International Non-Proprietary Name or INN.

UNSPSC 51151672 Tiemonium iodide is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally identifies a specific pharmaceutical compound, but the recent opportunities tagged under it involve naloxone (an opioid antagonist) and pharmacy benefit management services — products and services unrelated to tiemonium iodide's therapeutic class or chemical composition. State and local governments soliciting under this code are pursuing community health initiatives and pharmacy cost-management programs, not tiemonium iodide procurement. The issuing bodies include county health departments (Seminole County, Florida) and state health agencies (Texas Health and Human Services Commission), which are the typical buyers for pharmaceutical and pharmacy-administration services, but the tagged opportunities do not reflect purchases of the specific substance this code names.

Geographic activity is limited to Florida and Texas in the recent record. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission posted an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, a preliminary market-research phase preceding formal competitive procurement. The mismatch between the code's scope and these opportunities suggests the code is either misapplied in the state and local data, used as a catch-all placeholder for pharmaceutical purchases, or reflects a data-quality issue. Business development professionals pursuing pharmaceutical sales or pharmacy services to state and local buyers should monitor this code with caution and verify actual commodity alignment before responding.